Implantable Sensor Data Collection for Clinical Study Compliance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The current FDA drug approval process is time-consuming, costly, and inefficient, often delaying access to effective treatments and leading to public perception issues due to unforeseen side effects, while also failing to adequately serve niche patient populations with targeted drugs.

Innovation Solution

A centralized data collection system that interfaces with patients and clinicians to conduct clinical evaluations, utilizing implantable devices and external sensors to collect objective, real-time data on drug efficacy and safety, reducing human error and enabling remote monitoring and protocol adjustments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional FDA approval process is used, then drug safety and efficacy are evaluated, but the process is extremely time-consuming and costly

Engineering Contradiction:

Improvedrug safety evaluationVSAvoidapproval process duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The system performs preliminary data collection and analysis through implantable devices and sensors before formal FDA approval. Real-time physiological data, patient-reported outcomes, and adherence information are gathered during the approval process itself, allowing for accelerated evaluation while maintaining safety standards.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The system implements continuous feedback loops where patient data from implantable devices is constantly monitored and analyzed. This real-time feedback enables dynamic adjustment of evaluation criteria and accelerates the approval process by providing ongoing evidence of safety and efficacy rather than relying solely on periodic assessments.

Inventive Principle:

Principle #23Feedback

2Quantity of substance

If traditional clinical trial methods are used, then comprehensive data is collected, but human error and subjectivity reduce measurement accuracy

Engineering Contradiction:

Improvedata collection volumeVSAvoiddata accuracy

Core Design Contradiction:

Quantity of substanceVSMeasurement precision

Solution Approach 1:

The system replaces manual data collection and assessment methods with automated implantable devices and sensors. Objective physiological measurements from these devices eliminate human error in data recording, while algorithmic analysis replaces subjective clinician interpretation, significantly improving measurement precision while maintaining comprehensive data collection.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

Patients serve as their own monitoring subjects through implantable devices that automatically collect and transmit physiological data. This self-service approach eliminates the need for external observers to manually measure and record data, reducing human error while enabling continuous comprehensive monitoring.

Inventive Principle:

Principle #25Self-service

3Productivity

If FDA approval process is expedited, then access to treatments is improved, but safety monitoring may be compromised

Engineering Contradiction:

Improveapproval speedVSAvoidsafety monitoring

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The system enables continuous safety monitoring through implantable devices that operate without interruption throughout the approval process and beyond. This uninterrupted data collection maintains high safety monitoring standards while accelerating approval by providing real-time evidence rather than requiring extended periodic evaluation periods.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The implantable devices and centralized data analysis system serve as intermediaries between the drug and regulatory authorities. These intermediaries continuously monitor safety parameters and transmit objective data to FDA reviewers, enabling faster approval decisions while maintaining rigorous safety standards through automated, unbiased monitoring.

Inventive Principle:

Principle #24Intermediary (Mediator)

4Ease of operation

If traditional data collection methods are used, then compliance monitoring is performed, but patient adherence accuracy is low

Engineering Contradiction:

Improvecompliance monitoringVSAvoidadherence accuracy

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The system implements self-service compliance monitoring where implantable devices automatically track and report patient adherence to treatment protocols. Patients cannot easily falsify or misreport adherence data since the devices objectively measure actual drug administration and physiological responses, significantly improving accuracy while maintaining ease of operation through automated tracking.

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS7594889B2Integrated data collection and analysis for clinical study

Publication Date: 2009.09.29 MEDTRONIC INC

AI summary

A data collection system includes remote, implantable sensors for monitoring one or more patient parameters, collecting and processing data from those sensors and utilizing that data in the performance of a clinical study of a drug or other pharmacological agent. The system assists with preparation of a protocol for a clinical trial; presentation of that protocol; assuring compliance with the protocol; and generating useful results from data collected via the system and externally for presentation to an approval forum.